{"id":61661,"date":"2025-07-30T13:05:26","date_gmt":"2025-07-30T11:05:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ionis-reports-second-quarter-2025-financial-results-and-highlights-progress-on-key-programs\/"},"modified":"2025-07-30T13:05:26","modified_gmt":"2025-07-30T11:05:26","slug":"ionis-reports-second-quarter-2025-financial-results-and-highlights-progress-on-key-programs","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ionis-reports-second-quarter-2025-financial-results-and-highlights-progress-on-key-programs\/","title":{"rendered":"Ionis reports second quarter 2025 financial results and highlights progress on key programs"},"content":{"rendered":"
\n

\n– TRYNGOLZATM <\/sup>delivers $19 million in net product sales in the second quarter 2025 –<\/i><\/p>\n

\n– Donidalorsen approval in hereditary angioedema (HAE) anticipated next month; Ionis\u2019 second independent launch –<\/i><\/p>\n

\n– Phase 3 data from the pivotal CORE and CORE2 studies in severe hypertriglyceridemia (sHTG) expected in September 2025 –<\/i><\/p>\n

\n– Increasing 2025 financial guidance based on strong performance and improved outlook –<\/i><\/p>\n

CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the \u201cCompany\u201d) today reported financial results and provided key updates for the second quarter ended June 30, 2025.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cDuring the second quarter, we continued to build momentum across our business,\u201d said Brett P. Monia, Ph.D., chief executive officer of Ionis. \u201cOur strong performance included excellent commercial execution, resulting in a substantial increase in TRYNGOLZA revenues, our first independently launched medicine. We expect additional advancements in the second half, including Ionis\u2019 second independent launch with donidalorsen for hereditary angioedema, anticipated next month, and important Phase 3 results for olezarsen in severe hypertriglyceridemia and zilganersen in Alexander disease. We believe these four programs collectively represent multi-billion-dollar revenue potential and a transformational opportunity for Ionis and for patients.\u201d<\/p>\n

\nSecond Quarter 2025 Summary Financial Results(1)<\/sup>:<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n
\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nThree months ended<\/p>\n<\/td>\n

\n

\nSix months ended<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nJune 30,<\/p>\n<\/td>\n

\n

\nJune 30,<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2025<\/p>\n<\/td>\n

\n

\n2024<\/p>\n<\/td>\n

\n

\n2025<\/p>\n<\/td>\n

\n

\n2024<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n(amounts in millions)<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal revenue<\/p>\n<\/td>\n

\n

\n$452<\/p>\n<\/td>\n

\n

\n$225<\/p>\n<\/td>\n

\n

\n$584<\/p>\n<\/td>\n

\n

\n$345<\/p>\n<\/td>\n<\/tr>\n

\n

\nOperating expenses<\/p>\n<\/td>\n

\n

\n$312<\/p>\n<\/td>\n

\n

\n$291<\/p>\n<\/td>\n

\n

\n$591<\/p>\n<\/td>\n

\n

\n$560<\/p>\n<\/td>\n<\/tr>\n

\n

\nOperating expenses on a non-GAAP basis<\/p>\n<\/td>\n

\n

\n$282<\/p>\n<\/td>\n

\n

\n$260<\/p>\n<\/td>\n

\n

\n$532<\/p>\n<\/td>\n

\n

\n$498<\/p>\n<\/td>\n<\/tr>\n

\n

\nIncome (loss) from operations<\/p>\n<\/td>\n

\n

\n$140<\/p>\n<\/td>\n

\n

\n($66)<\/p>\n<\/td>\n

\n

\n($7)<\/p>\n<\/td>\n

\n

\n($215)<\/p>\n<\/td>\n<\/tr>\n

\n

\nIncome (loss) from operations on a non-GAAP basis<\/p>\n<\/td>\n

\n

\n$170<\/p>\n<\/td>\n

\n

\n($35)<\/p>\n<\/td>\n

\n

\n$52<\/p>\n<\/td>\n

\n

\n($153)<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n
<\/td>\n<\/td>\n\n

\n(1)<\/p>\n<\/td>\n

<\/td>\n\n

\nReconciliation of GAAP to non-GAAP basis contained later in this release.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nRecent Financial Highlights<\/b><\/p>\n